Trinity Biotech- Zahlen - 500 Beiträge pro Seite

[Biosektor]

Wer kann mir die genauen Zahlen von Trinity verraten?

Die Hompage ist noch nicht aktualisiert worden und ich habe
auf keiner anderen Seite eine Nachricht gefunden.

Beim Kurs koennte man denken, dass noch keine Zahlen bekanntgegeben
wurden.

Ich wuerde mich ueber eine Aufklaerung sehr freuen.

Biosektor

[Projekt_2005]

Die Zahlen sind da:Trinity Biotech Announces Year End Results

DUBLIN, Ireland, Feb. 8 /PRNewswire/ -- Trinity Biotech plc (Nasdaq: TRIB) today announced results for the three months and year ended December 31, 2000.

Profit after tax for the year ended December 31, 2000 rose 35% to US$6,111k (before exceptionals) compared to US$4,512k, (before exceptionals) in 1999. Revenues rose 14% to US$29,742k compared to US$26,104k last year. Because of the larger number of shares in issue, earnings per share rose at a slower rate of 3% to 16.46 cents per share (before exceptionals) for the financial year compared to 16.02 cents (before exceptionals) in 1999.

Profit after tax rose to US$1,375k (before exceptionals) on revenues of US$7,891k for the fourth quarter ended December 31, 2000, compared to US$1,298k (before exceptionals) on revenues of US$6,650k for the same period last year.

Earnings before interest, tax, amortisation and exceptionals (EBITDA) rose 33% to US$2,485k for the fourth quarter and 27% to US$8,455k for the year, compared to US$1,869k and US$6,669k respectively for the same period last year.

Following the acquisition of the Seattle based Bartels business in December, a decision was made to close the factory and transfer production to the San Diego, New York and Irish factories. This is now being implemented. An exceptional charge relating to the closure of US$1,287k arose in Q4, and a further exceptional charge of up to US$400k will arise in 2001. The financial benefits will accrue later in 2001.

Commenting on the results, Maurice Hickey, Chief Financial Officer, said "Trinity Biotech has produced another set of solid results in Q4 and a strong performance for the year as a whole. The profit for the quarter was adversely impacted by a higher than normal amortisation charge of US$625k following a review and realignment of our amortisation policy. While sales for the quarter were in excess of expectation, the gross margin dropped from 49% to 45%, due to an abnormally high percentage of sales into Africa and the Middle East, where margins are lower. While gross margins are expected to improve towards 50%, this factor combined with increased Irish payroll costs, arising from a shortage of labour, could result in operating profits for 2001 being 10% lower than analyst estimates. Overall, the year 2000 has been one of successful progress in strategic, financial and operational terms."

Ronan O`Caoimh, Chief Executive Officer, added, "Trinity has made excellent progress during fiscal 2000. We strengthened our balance sheet when we raised funds of $13.4m in April, and virtually eliminated all debt. We have increased our profit to $6.1m and have generated cash flows of $8.4m in the year. Our acquisition of MarDx has been most successful, while our acquisition of Bartels has added a high quality product range. For the first time, following these acquisitions, we are selling the Bartels and MarDx products directly into U.S. hospitals with our own sales force. Lastly our investment in HiberGen, a genomics company, as well as giving us an entry into molecular diagnostics, gives us a significant shareholding in a company which we believe has exceptional technology."

Trinity Biotech develops, manufactures and markets over 175 diagnostic products for the point-of-care, self-testing and clinical laboratory segments of the diagnostic market. Trinity Biotech sells worldwide in over 80 countries, through its own sales force and through a network of 280 international distributors and strategic partners.

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company`s periodic reports filed with the Securities and Exchange Commission.


Trinity Biotech plc
Consolidated Statement of Operations

(US$000`s except share data)

Three Months Three Months Year Year
Ended Ended Ended Ended
Dec. 31, Dec. 31, Dec. 31, Dec. 31,
2000 1999 2000 1999

Revenues 7,891 6,650 29,742 26,104

Cost of goods sold (4,350) (3,365) (15,401) (14,521)

Gross profit 3,541 3,285 14,341 11,583

Research & development
expenses (342) (755) (2,712) (2,448)
Administrative
expenses - normal (904) (821) (3,878) (3,106)
- exceptional (1,287) 0 (1,287) 0
Amortisation of goodwill (625) (260) (1,277) (863)

Operating profit 383 1,449 5,187 5,166

Net profit (loss)
on disposal of assets 0 1,014 0 1,014
Write down of financial
assets 0 (610) 0 (610)
Interest receivable &
similar income 131 15 466 69
Interest payable &
similar charges (302) (166) (705) (723)

Profit on ordinary
activities before tax 212 1,702 4,948 4,916
Tax on profit on ordinary
activities (124) 0 (124) 0
Profit after tax 88 1,702 4,824 4,916

Earnings per share
(in US cents) 0.22 5.93 12.99 17.46
Adjusted earnings
per share
before exceptionals
(in US cents) 3.51 4.52 16.46 16.02

Diluted earnings per share
(in US cents) 0.28 5.72 12.20 16.96
Adjusted diluted earnings
per share
before exceptionals
(in US cents) 3.29 4.36 15.37 15.56

Weighted average
no. of shares 39,143,743 28,703,922 37,131,692 28,158,184


Trinity Biotech plc
Consolidated Balance Sheet

December 31, 2000 December 31, 1999

US$000`s US$000`s

ASSETS
Cash and cash equivalents 4,046 3,064
Short term investments -- --
Accounts receivable and prepayments 7,987 7,212
Inventories 14,412 9,510

TOTAL CURRENT ASSETS
Property, plant & equipment, net 5,469 4,696
Intangible assets, net 33,761 20,559
Financial assets 1,342 --

TOTAL ASSETS 67,017 45,041

LIABILITIES & SHAREHOLDERS` EQUITY
Accounts payable & accrued expenses 10,231 13,770
Long term liabilities 2,266 8,086

SHAREHOLDERS` EQUITY
Called up share capital
Class "A" common shares 590 447
Class "B" common shares 12 12
Share premium account 75,258 47,863
Revenue and other reserves -21,340 -25,137

TOTAL LIABILITIES &
SHAREHOLDERS` EQUITY 67,017 45,041



/CONTACT: Maurice Hickey of Trinity Biotech plc, [phone], or [e-mail]/

[thomy18]

Könnte besser sein!!

Amerika minus 6 Prozent!



Trinity Biotech Announces Year End Results

DUBLIN, Ireland, Feb. 8 /PRNewswire/ -- Trinity Biotech plc (Nasdaq: TRIB) today announced results for the three months and year ended December 31, 2000.

Profit after tax for the year ended December 31, 2000 rose 35% to US$6,111k (before exceptionals) compared to US$4,512k, (before exceptionals) in 1999. Revenues rose 14% to US$29,742k compared to US$26,104k last year. Because of the larger number of shares in issue, earnings per share rose at a slower rate of 3% to 16.46 cents per share (before exceptionals) for the financial year compared to 16.02 cents (before exceptionals) in 1999.

Profit after tax rose to US$1,375k (before exceptionals) on revenues of US$7,891k for the fourth quarter ended December 31, 2000, compared to US$1,298k (before exceptionals) on revenues of US$6,650k for the same period last year.

Earnings before interest, tax, amortisation and exceptionals (EBITDA) rose 33% to US$2,485k for the fourth quarter and 27% to US$8,455k for the year, compared to US$1,869k and US$6,669k respectively for the same period last year.

Following the acquisition of the Seattle based Bartels business in December, a decision was made to close the factory and transfer production to the San Diego, New York and Irish factories. This is now being implemented. An exceptional charge relating to the closure of US$1,287k arose in Q4, and a further exceptional charge of up to US$400k will arise in 2001. The financial benefits will accrue later in 2001.

Commenting on the results, Maurice Hickey, Chief Financial Officer, said "Trinity Biotech has produced another set of solid results in Q4 and a strong performance for the year as a whole. The profit for the quarter was adversely impacted by a higher than normal amortisation charge of US$625k following a review and realignment of our amortisation policy. While sales for the quarter were in excess of expectation, the gross margin dropped from 49% to 45%, due to an abnormally high percentage of sales into Africa and the Middle East, where margins are lower. While gross margins are expected to improve towards 50%, this factor combined with increased Irish payroll costs, arising from a shortage of labour, could result in operating profits for 2001 being 10% lower than analyst estimates. Overall, the year 2000 has been one of successful progress in strategic, financial and operational terms."

Ronan O`Caoimh, Chief Executive Officer, added, "Trinity has made excellent progress during fiscal 2000. We strengthened our balance sheet when we raised funds of $13.4m in April, and virtually eliminated all debt. We have increased our profit to $6.1m and have generated cash flows of $8.4m in the year. Our acquisition of MarDx has been most successful, while our acquisition of Bartels has added a high quality product range. For the first time, following these acquisitions, we are selling the Bartels and MarDx products directly into U.S. hospitals with our own sales force. Lastly our investment in HiberGen, a genomics company, as well as giving us an entry into molecular diagnostics, gives us a significant shareholding in a company which we believe has exceptional technology."

Trinity Biotech develops, manufactures and markets over 175 diagnostic products for the point-of-care, self-testing and clinical laboratory segments of the diagnostic market. Trinity Biotech sells worldwide in over 80 countries, through its own sales force and through a network of 280 international distributors and strategic partners.

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company`s periodic reports filed with the Securities and Exchange Commission.


Trinity Biotech plc
Consolidated Statement of Operations

(US$000`s except share data)

Three Months Three Months Year Year
Ended Ended Ended Ended
Dec. 31, Dec. 31, Dec. 31, Dec. 31,
2000 1999 2000 1999

Revenues 7,891 6,650 29,742 26,104

Cost of goods sold (4,350) (3,365) (15,401) (14,521)

Gross profit 3,541 3,285 14,341 11,583

Research & development
expenses (342) (755) (2,712) (2,448)
Administrative
expenses - normal (904) (821) (3,878) (3,106)
- exceptional (1,287) 0 (1,287) 0
Amortisation of goodwill (625) (260) (1,277) (863)

Operating profit 383 1,449 5,187 5,166

Net profit (loss)
on disposal of assets 0 1,014 0 1,014
Write down of financial
assets 0 (610) 0 (610)
Interest receivable &
similar income 131 15 466 69
Interest payable &
similar charges (302) (166) (705) (723)

Profit on ordinary
activities before tax 212 1,702 4,948 4,916
Tax on profit on ordinary
activities (124) 0 (124) 0
Profit after tax 88 1,702 4,824 4,916

Earnings per share
(in US cents) 0.22 5.93 12.99 17.46
Adjusted earnings
per share
before exceptionals
(in US cents) 3.51 4.52 16.46 16.02

Diluted earnings per share
(in US cents) 0.28 5.72 12.20 16.96
Adjusted diluted earnings
per share
before exceptionals
(in US cents) 3.29 4.36 15.37 15.56

Weighted average
no. of shares 39,143,743 28,703,922 37,131,692 28,158,184


Trinity Biotech plc
Consolidated Balance Sheet

December 31, 2000 December 31, 1999

US$000`s US$000`s

ASSETS
Cash and cash equivalents 4,046 3,064
Short term investments -- --
Accounts receivable and prepayments 7,987 7,212
Inventories 14,412 9,510

TOTAL CURRENT ASSETS
Property, plant & equipment, net 5,469 4,696
Intangible assets, net 33,761 20,559
Financial assets 1,342 --

TOTAL ASSETS 67,017 45,041

LIABILITIES & SHAREHOLDERS` EQUITY
Accounts payable & accrued expenses 10,231 13,770
Long term liabilities 2,266 8,086

SHAREHOLDERS` EQUITY
Called up share capital
Class "A" common shares 590 447
Class "B" common shares 12 12
Share premium account 75,258 47,863
Revenue and other reserves -21,340 -25,137

TOTAL LIABILITIES &
SHAREHOLDERS` EQUITY 67,017 45,041



/CONTACT: Maurice Hickey of Trinity Biotech plc, [phone], or [e-mail]/
Home | About Nasdaq | Feedback | Help & Reference
Equity & Index Options | Site Map, Index, Tour, Search